Belite Bio, Inc (BLTE) Financial Ratios
5 years of historical data (2020–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
32.67
↑+138% vs avg
5yr avg: 13.73
30Y Low13.2·High14.5
ROE
↑
-30.6%
↓+47% vs avg
5yr avg: -58.1%
30Y Low-96%·High-31%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BLTE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Belite Bio, Inc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $5.0B | $1.9B | $1.2B | $602M | — | — |
| Enterprise Value | $4.9B | $1.9B | $1.1B | $561M | — | — |
| P/E Ratio → | -132.20 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 32.67 | 13.21 | 13.45 | 14.51 | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BLTE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
BLTE Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -30.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -30.6% | -30.6% | -48.0% | -95.8% | — | — |
| ROA | -29.3% | -29.3% | -45.5% | -40.4% | -43.8% | -22.3% |
| ROIC | -50.9% | -50.9% | -1381.7% | — | — | — |
| ROCE | -33.7% | -33.7% | -47.6% | -43.5% | -47.2% | -23.2% |
BLTE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $32M exceeds total debt of $537000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.01 | 0.02 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.21 | -0.97 | -0.99 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -1999.80 | -1999.80 | -1266.72 | -801.31 | — | -273.48 |
Net cash position: cash ($32M) exceeds total debt ($537000)
BLTE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Belite Bio, Inc's current ratio of 24.31x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 20.35x to 24.31x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 24.31 | 24.31 | 24.76 | 20.35 | 10.66 | 26.41 |
| Quick Ratio | 24.31 | 24.31 | 24.76 | 20.35 | 10.66 | 26.41 |
| Cash Ratio | 23.99 | 23.99 | 24.27 | 20.00 | 10.61 | 26.36 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
BLTE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Belite Bio, Inc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $31M | $27M | $20M | $24M | $9M |
Peer Comparison
Compare BLTE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BLTEYou | $5B | -132.2 | — | — | — | — | -30.6% | -50.9% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 REPL | $266M | -1.1 | — | — | — | — | -62.6% | -51.9% | — |
 KRYS | $9B | 43.4 | 49.2 | 46.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 EDIT | $297M | -1.7 | — | — | — | — | -198.1% | — | — |
 BEAM | $3B | -38.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 RARE | $3B | -4.5 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 REGN | $74B | 17.1 | 17.8 | 18.1 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 NVS | $277B | 20.2 | 13.5 | 15.7 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 ABBV | $358B | 85.5 | 15.0 | 20.1 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See BLTE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BLTE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BLTE vs ACAD
Side-by-side business, growth, and profitability comparison vs ACADIA Pharmaceuticals Inc..
Start ComparisonBLTE — Frequently Asked Questions
Quick answers to the most common questions about buying BLTE stock.
What is Belite Bio, Inc's P/E ratio?
Belite Bio, Inc's current P/E ratio is -132.2x. This places it at the 50th percentile of its historical range.
What is Belite Bio, Inc's ROE?
Belite Bio, Inc's return on equity (ROE) is -30.6%. The historical average is -58.1%.
Is BLTE stock overvalued?
Based on historical data, Belite Bio, Inc is trading at a P/E of -132.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.